What Is Margetuximab-cmkb (Margenza)? FDA Approval, Licensing in Türkiye, and Reimbursement Status

• FDA Approved: Yes (Approval Date: December 16, 2020)
• Brand Name: Margenza
• Active Ingredient: Margetuximab-cmkb
• Administration: Intravenous infusion (through a vein)
• Drug Class: Monoclonal antibody, Anti-HER2 agent
• Category: Targeted therapy and immunotherapeutic agent
• Manufacturer: MacroGenics, Inc.
• Distribution in Türkiye: Currently not licensed in Türkiye.
• Approved Cancer Types: Metastatic HER2-positive breast cancer (Approved with chemotherapy for HER2-positive metastatic breast cancer in patients previously receiving two or more anti-HER2 regimens.)

What Is Margetuximab-cmkb? How Does It Work?

Margetuximab-cmkb, marketed as Margenza, is a recombinant immunoglobulin G1 (IgG1) monoclonal antibody used particularly to treat HER2-positive metastatic breast cancer.

How Does It Work?

• Binds to the HER2 receptor: HER2 is a growth factor receptor present in excessive amounts on breast cancer cell surfaces.
• Blocks signal transmission: Signals promoting cell proliferation and survival through HER2 are blocked.
• Increases ADCC activity: Margetuximab’s Fc region is specifically modified, giving the immune system greater capacity to attack tumor cells than with trastuzumab.
• Binds more strongly to the CD16A receptor: This receptor is found on immune cells; margetuximab’s high affinity for it initiates an effective immune response.

Margetuximab therefore both suppresses tumor growth and mobilizes the immune system against the tumor.

FDA (US Food and Drug Administration) Approval History

• December 16, 2020: The FDA approved Margenza (margetuximab-cmkb) for previously treated patients with metastatic HER2-positive breast cancer.
• December 19, 2019: MacroGenics announced submission of a Biologics License Application for margetuximab to the US Food and Drug Administration (FDA).

Licensing in Türkiye

This drug is not yet licensed in our country. It is not on the TİCK overseas drug list.

Resistance Mechanisms 

As resistance can develop to HER2-targeted therapies (including trastuzumab), certain resistance mechanisms may also occur with margetuximab. The most common include:

Reduced or Lost HER2 Expression:

• Tumor cells begin producing less HER2 protein.
• When the target protein disappears, antibody efficacy decreases.

Activation of Alternative Signaling Pathways:

• Alternative cellular growth pathways such as PI3K/AKT/mTOR or MAPK may activate.
• This renders HER2 inhibition ineffective.

Fc Receptor Polymorphisms (Genetic Factors):

• Margetuximab is designed to bind more effectively to the FcγRIIIa (CD16A) receptor.
• However, polymorphic receptor variants in some individuals may reduce binding and ADCC effects.

An Immunosuppressive Tumor Microenvironment:

• High levels of immunosuppressive factors such as TGF-β, IL-10, and PD-L1 around the tumor prevent immune-mediated tumor killing.
• Margetuximab’s ADCC effect weakens.

Absorption

• Administered by intravenous (IV) infusion.
• No oral bioavailability (monoclonal antibodies cannot be absorbed through the digestive system).
• Absorption is bypassed; it enters systemic circulation directly.

Distribution

• Volume of distribution (Vd): ~4.5 L
• This indicates that the drug remains largely confined to plasma, with limited tissue distribution (as expected).
• It does not bind extensively to plasma proteins.
• Binds selectively to tumor regions expressing HER2.

Metabolism

• Not conventionally metabolized by liver enzymes (e.g., CYP450).
• The body breaks it down through proteolysis; it is taken up by the reticuloendothelial system (particularly macrophages). It is degraded into amino acids for reuse or elimination.

Elimination

• Not excreted through a specific organ (e.g., kidneys or bile).
• As with monoclonal antibodies generally, it is broken down mainly through the reticuloendothelial system; degradation products are reused or eliminated.

Dosing Schedule 

• A clear to slightly opalescent solution, ranging from colorless to pale yellow or light brown, supplied in a single-dose vial containing 250 mg/10 mL (25 mg/mL).
• Recommended Dose: 15 mg/kg, calculated using the patient’s actual body weight.
• Administered every 3 weeks (every 21 days), scheduled to align with chemotherapy cycles.
• First infusion: approximately 120 minutes; subsequent infusions (if no serious reaction occurred initially): approximately 30–60 minutes.
• Premedication before infusion (e.g., antihistamine and antipyretic) is recommended to prevent infusion reactions.
• LVEF (left ventricular ejection fraction) should be assessed for cardiac toxicity, particularly because the risk resembles that of HER2 drugs such as trastuzumab.

Drug Interactions 

CYP450 Interactions: Margetuximab is not metabolized by the CYP450 enzyme system and therefore does not directly interact with drugs using this system. (Interaction risk with CYP450-affected drugs such as warfarin, statins, or antidepressants is consequently very low.)

Interactions with Immunosuppressants: Margetuximab’s action largely depends on immune activation (ADCC, NK-cell activity). If the patient takes corticosteroids, immunosuppressants, or other immune-suppressing drugs (e.g., methotrexate, cyclosporine):

• The immune system may be suppressed.
• Margetuximab efficacy may decrease.

Interactions in Combination Therapy: Chemotherapy Agents (e.g., Capecitabine): Clinically safe to use together. However, toxicities such as bone marrow suppression (neutropenia) may increase, requiring dose adjustments. Shared gastrointestinal effects (nausea, diarrhea) may be synergistic. Combination with Other Anti-HER2 Agents: Combining with drugs such as trastuzumab or pertuzumab is not recommended because they share a target, creating overlapping effects + toxicity risk.

Use with Cardiotoxic Drugs: Because margetuximab targets the HER2 pathway, it may affect cardiac function (like trastuzumab). Caution is needed if the patient uses anthracyclines (such as doxorubicin) or drugs that can prolong QT. Cardiac function (LVEF) should be monitored regularly.

Precautions

Cardiac Toxicity Risk:

• The HER2 receptor is also found in heart muscle cells.
• Left ventricular ejection fraction (LVEF) may fall, and heart failure may develop.
• Risk is particularly increased in patients previously treated with anthracyclines.
• Cardiac function should be monitored regularly before and during treatment (e.g., echocardiography every 3 months).

 Infusion Reactions

Acute infusion reactions such as fever, chills, dizziness, nausea, or breathlessness may occur with initial or later doses. Therefore:

• The first infusion is given slowly over 120 minutes.
• Premedication (antihistamine + antipyretic ± steroid) is recommended.
• If a reaction occurs, stop the infusion and provide symptomatic treatment.

Immunosuppressive Conditions

• Margetuximab’s action depends on immune system activation.
• If the patient receives immunosuppressive treatment (corticosteroids, methotrexate, cyclosporine, etc.), drug efficacy may decrease.
• Use in these patients requires careful assessment.

Pregnancy and Breastfeeding

• Margetuximab can cross the placenta and cause fetal toxicity, particularly affecting immune system development.
• Pregnancy category: Unknown (but considered risky based on other anti-HER2 agents).
• Use in pregnant or breastfeeding women is not recommended.
• Women of childbearing potential should be advised to use effective contraception during treatment and for at least 4 months afterward.

Sensitivity to Genetic Variations

• Margetuximab shows greater binding to genetic variants of the FcγRIIIa (CD16A) receptor (e.g., the V158F polymorphism).
• This may produce stronger immune responses in some patients.
• Individual genetic differences may influence treatment.

 Disease Progression and Intolerance

• Treatment should be discontinued with disease progression or severe toxicity.
• Because it is generally used with chemotherapy rather than alone, the entire treatment regimen should be assessed together.

Side Effects

• Fatigue 57%
• Nausea 38%      
• Diarrhea 34%      
• Mouth sores (stomatitis/mucositis) 32%
• Hand–foot syndrome (palmar-plantar erythrodysesthesia) 29%              
• Fever (pyrexia) 28%      
• Vomiting 26%      
• Rash 25%
• Neutropenia (decreased white blood cells) 22%              
• Headache 20%
• Infusion-related reactions 13%
• Anemia (low red blood cells) 11%
• Loss of appetite 10%
• Severe neutropenia 12%
• Severe diarrhea 6%              
• Severe hand–foot syndrome 5%
• Cardiac dysfunction (reduced LVEF) <2%

These data come particularly from the SOPHIA Phase 3 trial and are based on use with capecitabine.